This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study. This is an important step for our Phase
Imagion Biosystems announced on 10 May 2021 that it has received a total of $44,545.32 for the exercise of options. The total was composed of
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 10 May, 2021. Please click to review the
Imagion Biosystems is pleased to announce a partnership with the ASX-listed therapeutic antibody development company Patrys Limited. The collaborative research program aims to combine Imagion Biosystems
Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study
Imagion Biosystems announced on ASX that it has received a total of $164,754 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on April 26, 2021. Please click to review the
Imagion Biosystems announced on ASX that it has received a total of $81,256.85 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on April 13, 2021. Please click to review the
Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance